Nrf2-mediated macrophage function in benign prostatic hyperplasia: Novel molecular insights and implications

Biomed Pharmacother. 2023 Nov:167:115566. doi: 10.1016/j.biopha.2023.115566. Epub 2023 Sep 29.

Abstract

One of the most common urological diseases is benign prostatic hyperplasia (BPH), with a high prevalence in the middle-aged and elderly male population. Patient's mental and physical health is affected significantly by this condition, causing them considerable discomfort. During the development of BPH, a synergistic effect occurs in response to inflammation, oxidative stress, and apoptosis induced by the activation of macrophages. The nuclear factor erythroid2-related factor 2 (Nrf2) signaling pathway can mediate macrophage activation and inhibit prostate hyperplasia by suppressing pro-inflammatory factors, anti-oxidative stress disorder, and initiating apoptosis. The purpose of this study was to review the mechanism of action of Nrf2 signaling pathway-mediated macrophage activation on the immune microenvironment of BPH and to summarize the Chinese medicine based on Nrf2 to provide an overview of BPH treatment options.

Keywords: Benign prostate hyperplasia; Chinese medicine; Immune microenvironment; Macrophages; Nrf2 signaling pathway.

Publication types

  • Review

MeSH terms

  • Aged
  • Humans
  • Inflammation / metabolism
  • Macrophages / metabolism
  • Male
  • Middle Aged
  • NF-E2-Related Factor 2 / metabolism
  • Prostatic Hyperplasia* / metabolism
  • Signal Transduction

Substances

  • NF-E2-Related Factor 2
  • NFE2L2 protein, human